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Multiple Pathways of Escape from HIV Broadly Cross-Neutralizing
V2-Dependent Antibodies
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Centre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africaa; University of the
Witwatersrand, Johannesburg, South Africab; Institute of Infectious Disease and Molecular Medicine, Division of Medical Virology, University of Cape Town and National
Health Laboratory Service, Cape Town, South Africac; Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu Natal, Durban, South
Africad
Broadly cross-neutralizing (BCN) antibodies are likely to be critical for an effective HIV vaccine. However, the ontogeny of such
antibodies and their relationship with autologous viral evolution is unclear. Here, we characterized viral evolution in CAP256, a
subtype C-infected individual who developed potent BCN antibodies targeting positions R166 and K169 in the V2 region.
CAP256 was superinfected at 3 months postinfection with a virus that was highly sensitive to BCN V2-dependent monoclonal
antibodies. The autologous neutralizing response in CAP256 was directed at V1V2, reaching extremely high titers (>1:40,000)
against the superinfecting virus at 42 weeks, just 11 weeks prior to the development of the BCN response targeting the same re-
gion. Recombination between the primary and superinfecting viruses, especially in V2 and gp41, resulted in two distinct lineages
by 4 years postinfection. Although neutralization of some CAP256 clones by plasma from as much as 2 years earlier suggested
incomplete viral escape, nonetheless titers against later clones were reduced at least 40-fold to less than 1:1,000. Escape muta-
tions were identified in each lineage, either at R166 or at K169, suggesting that strain-specific and BCN antibodies targeted over-
lapping epitopes. Furthermore, the early dependence of CAP256 neutralizing antibodies on the N160 glycan decreased with the
onset of neutralization breadth, indicating a change in specificity. These data suggest rapid maturation, within 11 weeks, of
CAP256 strain-specific antibodies to acquire breadth, with implications for the vaccine elicitation of BCN V2-dependent anti-
bodies. Overall these studies demonstrate that ongoing viral escape is possible, even from BCN antibodies.
Neutralizing antibodies (NAbs) develop in almost all HIV-1-infected individuals in the first months following infection
(1–3). However, these early NAbs are extremely strain specific,
neutralizing only the autologous viruses from that individual (1–
3). This is because they target the variable regions of the viral
envelope, including the V1V2 and C3V4 regions (4–7). Viral es-
cape from these strain-specific NAbs occurs rapidly, thus circulat-
ing viruses are seldom neutralized by contemporaneous sera,
though they are sensitive to subsequent waves of NAbs (1, 2, 4, 5,
7–9). This process, which is ongoing for many years, results in
envelope diversification and the generation of viral quasispecies
that often show differences in neutralization sensitivity.
The development of broadly cross-neutralizing (BCN) anti-
bodies, those with the capacity to neutralize heterologous viruses
across many genetic subtypes, occurs only in about a quarter of
HIV-1-infected people (10–15). Recently, there has been intense
interest in mapping the targets of BCN antibodies in polyclonal
sera and in isolating and characterizing BCN monoclonal anti-
bodies (MAbs) from infected subjects. These studies have shown
that the majority of the BCN activity is due to antibodies that
target four sites on the HIV-1 envelope. These include the CD4
binding site (defined by the MAbs IgG1b12, VRC01, HJ16, and
CH31), the gp41 membrane-proximal external region (MAbs
4E10, 2F5, and 10e8), a peptidoglycan epitope at the base of the V3
loop (MAbs 2G12, PG121, PGT128, and PGT135), and a pepti-
doglycan epitope in the V2 region (MAbs PG9, PG16, PGT141-
145, and CH01-04) (1, 14–20). Since the epitopes defined by these
MAbs represent vulnerable sites on the HIV-1 envelope, under-
standing the ontogeny of these types of antibody specificities
could help to develop a preventative HIV vaccine that emulates
this process.
To date, the development of BCN antibodies has been shown
to be associated with the duration of infection, high viral load, low
CD4 T cell counts, and viral diversity and evolution (10–13, 21,
22), the latter suggesting that viral factors play a key role in this
process. It is not known whether BCN antibodies arise by affinity
maturation of earlier strain-specific NAbs or whether neutraliza-
tion breadth is a consequence of de novo specificities, which
through chance target more conserved epitopes. The fact that
BCN antibodies normally take 2 to 3 years to appear (11) and the
high levels of somatic hypermutation displayed by many BCN
MAbs suggests a requirement for antibody maturation rather than
simply a stochastic event. While the V1V2 and C3 regions are
targets of both strain-specific early antibodies and later BCN an-
tibodies (4–7, 11, 14, 15, 23, 24), the relationship between these
antibodies and their impact on autologous viral evolution has not
been well characterized. Data on viral escape from antibodies tar-
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geting conserved epitopes is limited, as many individuals who de-
velop BCN antibodies were identified in cross-sectional cohorts of
chronically infected individuals. In a recent study of autologous
viral populations in the subject from whom the VRC01 MAb was
isolated, efficient and ongoing viral escape, with viruses resistant
to contemporaneous neutralization, was described in parallel with
ongoing evolution of the BCN CD4 binding site antibody re-
sponse (25). The possibility of viral escape, even from BCN anti-
bodies targeting highly conserved epitopes, is consistent with the
fact that the development of such antibodies does not confer a
clinical benefit to those individuals (10, 11). This further suggests
that viral escape from such responses does not incur significant
fitness costs, as has been suggested elsewhere (26). Nonetheless,
understanding viral evolution and defining the pathways to viral
escape in individuals who develop BCN antibodies may provide
insights into how such antibodies are elicited.
The V1V2 region was known to contain conserved elements
that are recognized by BCN NAbs. This was confirmed by the
recent structural analysis of a scaffolded subtype C V1V2 bound to
the BCN MAb PG9 (27). This structure showed that V1V2 forms
a four-stranded -sheet domain, in which sequence variation and
glycosylation are largely limited to loops that connect the strands,
although alternative conformations of V1V2 may exist (28). In-
terest in the V2 region intensified following the case control anal-
ysis of the RV144 Thai vaccine trial that exhibited moderate (31%)
efficacy, which identified V2 binding antibodies as a correlate of
protection (29). Sieve analysis of break-through infections sug-
gested immune pressure at residue 169 in the C beta strand of the
V2 region (30), and MAbs isolated from RV144 vaccinees showed
dependence on K169 (28). This finding, along with the previously
defined dependence of the BCN MAbs PG9/PG16 (15, 31) and
polyclonal BCN plasma (31) on this residue, suggests a need to
better understand antibodies targeting this region.
We have previously described CAP256, a subtype C superin-
fected individual who developed potent BCN antibodies targeting
a quaternary neutralizing epitope involving the V2 region (31),
similar to the PG9 and PG16 MAbs (15). Fine mapping showed
that the CAP256 BCN antibody was dependent on residues F159,
N160, L165, R166, D167, K169, and K171 (forming the FN/LRD-
K-K motif). Interestingly, the fine specificity of the evolving anti-
body response changed over time, including dependence on the
glycan at position 160 that is crucial for recognition by PG9 and
PG16 (31). Here, we have examined viral populations in CAP256
and characterized different pathways of neutralization escape
from autologous antibodies. We show that the early strain-specific
response, like the BCN response, targets the V1V2 region of both
the primary infecting (PI) virus and the superinfecting (SU) virus.
However, the response was largely directed at the superinfecting
virus with extremely high titers, reminiscent of CAP256 heterolo-
gous neutralization. We further showed that in the context of
extensive recombination, neutralization escape occurred via
amino acid substitutions at residues 166 and 169 in the FN/LRD-
K-K motif. These data provide insights into how HIV evades neu-
tralizing antibodies that target the V2 region.
MATERIALS AND METHODS
CAPRISA participant CAP256. CAP256 was enrolled into the CAPRISA
Acute Infection study (32) that was established in 2004 in KwaZulu-Natal,
South Africa. This study was reviewed and approved by the research ethics
committees of the University of KwaZulu-Natal (E013/04), the University
of Cape Town (025/2004), and the University of the Witwatersrand
(MM040202). CAP256 provided written informed consent for study par-
ticipation. The kinetics and specificity of BCN antibodies in CAP256 has
been described in detail elsewhere (11, 31).
SGA and sequencing of CAP256 envelope genes. HIV-1 RNA was
purified from plasma using the Qiagen Viral RNA kit and reverse tran-
scribed to cDNA using Superscript III Reverse Transcriptase (Invitrogen,
CA). The env genes were amplified from single-genome templates as de-
scribed previously (33). Amplicons were directly sequenced using the ABI
PRISM BigDye Terminator Cycle Sequencing Ready Reaction kit (Ap-
plied Biosystems, Foster City, CA) and resolved on an ABI 3100 auto-
mated genetic analyzer. The full-length env sequences were assembled and
edited using Sequencher v.4.0 software (Genecodes, Ann Arbor, MI). For
strain-specific single-genome amplification (SGA) of the CAP256 super-
infecting virus, reverse transcription was performed using a primer spe-
cific for the superinfecting variant (256spR; 5=-CTCCCTCTGCTGTTGG
CTGCGCTCGCGC-3=; HXB2 positions 8856 to 8884; Nef). SGA was
performed as described above, using the strain-specific primer as the anti-
sense primer in both rounds of amplification. Multiple-sequence alignments
were performed using Clustal X (version 1.83) and edited with BioEdit (ver-
sion 5.0.9). Sequence alignments were visualized using Highlighter for Amino
Acid Sequences v1.1.0 (beta) (http://www.hiv.lanl.gov/content/sequence
/HIGHLIGHT/HIGHLIGHT_POSTSCRIPT/highlighter.html). Recombi-
nation was assessed using the RIP tool (http://www.hiv.lanl.gov/content
/sequence/RIP/RIP.html). Pairwise DNA distances and neighbor-joining
trees were computed using MEGA 4 (34). Three genotypic coreceptor
prediction algorithms, namely, C-PSSM (35), geno2pheno (36), and the
11/25 rule (37), were used to predict the coreceptor use of each envelope
sequence.
Cloning CAP256 envelopes and production of pseudoviruses. Se-
lected amplicons were cloned into the expression vector pCDNA 3.1 (di-
rectional) (Invitrogen) by reamplification of SGA first-round products
using Phusion enzyme (Finn Enzymes) with the EnvM primer (38) and a
directional primer, EnvAdir (4). Cloned env genes were sequenced as
described above. The full-length gp160 sequences were assembled and
edited using Sequencher v.4.0 software (Genecodes, Ann Arbor, MI).
Cloned envelopes were shown to match the amino acid sequences of SGA-
derived sequences exactly.
Cell lines. The JC53bl-13 cell line, engineered by J. Kappes and X. Wu,
was obtained from the NIH AIDS Research and Reference Reagent Pro-
gram. 293T cells were obtained from George Shaw (University of Ala-
bama, Birmingham, AL). Both cell lines were cultured in Dulbecco’s mod-
ified Eagle medium (DMEM; Gibco BRL Life Technologies) containing
10% heat-inactivated fetal bovine serum and 50 g/ml gentamicin
(Sigma). Cell monolayers were disrupted at confluence by treatment with
0.25% trypsin in 1 mM EDTA.
TZM-bl neutralization assays. Env-pseudotyped viruses were ob-
tained by cotransfecting the Env plasmid with pSG3Env (3) using
Fugene transfection reagent (Roche) as previously described (1). Neu-
tralization was measured as described previously (1) by a reduction in
luciferase gene expression after single-round infection of JC53bl-13
cells with Env-pseudotyped viruses. Titers were calculated as the re-
ciprocal plasma dilution causing a 50% reduction of relative light units
(ID50).
Generation of chimeras and mutant envelopes. Chimeric V1V2 en-
velopes were created using an overlapping PCR strategy with the inserts
and flanking regions amplified in separate reactions. After linkage, the
3-kb chimeric PCR fragments, generated using primers EnvAdir and
EnvM (38), were cloned into pCDNA 3.1 (directional) (Invitrogen) and
screened for function as previously described (39). Chimerism was con-
firmed by sequence analysis. Site-directed mutagenesis was performed
using the Stratagene QuikChange II kit (Stratagene) as recommended by
the manufacturer.
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Superinfection of CAP256 by a subtype C virus shortly after pri-
mary infection. CAP256 is a subtype C-infected individual in the
CAPRISA 002 cohort who developed potent BCN antibodies that
preferentially neutralized subtype C viruses (11, 31). Mapping of
the BCN antibodies at 3 years of infection showed that they tar-
geted residues in the V2 region within the context of the envelope
trimer, similar to the PG9/16 MAbs. Despite the development of
BCN antibodies, CAP256 required antiretroviral treatment at 4
years of infection after developing tuberculosis (Fig. 1).
In order to examine viral escape from the BCN response in
CAP256, SGA-derived envelope sequences were generated from
plasma at 1 month (enrollment into the study) and at 6, 12, 21,
and 39 months postinfection (p.i.) (Fig. 1; sequence alignment of
the complete V1V2 is shown in Fig. S1 in the supplemental mate-
rial). Sequence analysis showed unusually high genetic variability
(up to 10.8% in gp160) by 6 months of infection that was incon-
sistent with the short duration of infection. This, in conjunction
with the observation that the viral load of CAP256 transiently
increased nearly 50-fold from 51,600 copies/ml at 13 weeks p.i. to
2,390,000 copies/ml at 15 weeks before declining again to 141,000
copies/ml by 17 weeks (Fig. 1), suggested the possibility of super-
infection.
To identify the potential superinfecting virus, a strain-specific
primer was designed based on the sequences of later presumed
recombinant viruses. Strain-specific single-genome PCR amplifi-
cation (SS-SGA) was performed using plasma from 6, 11, 13, and
15 weeks p.i., corresponding to the earliest available sample and
those prior to and at the peak of the viral load spike at 15 weeks p.i.
(Fig. 1). While no amplification was evident in the samples from 6,
11, and 13 weeks p.i., a phylogenetically distinct envelope was
successfully amplified at 15 weeks p.i., suggesting that superinfec-
tion occurred between 13 and 15 weeks after the initial infection.
Consistent with this, the 6 amplicons sequenced from 15 weeks
were highly homogenous, suggesting that they had been recently
transmitted. Furthermore, there was no evidence of recombina-
tion with the initial virus at this time point using the Recombina-
tion Identification Program (RIP) of the Los Alamos Sequence
Database, with a window size of 100 bp and a background align-
ment, including sequences from the initial virus (data not shown).
The superinfecting virus is highly sensitive to early CAP256
NAbs. In order to measure viral escape from BCN NAbs and ear-
lier strain-specific responses, selected amplicons were cloned from
each time point and used to generate functional pseudoviruses for
use in the TZMbl neutralization assay. Clone 256.1mo.C7
matched the consensus sequence from the enrollment time point
and was assumed to reflect the transmitted/founder virus of
the primary infecting (PI) virus. Similarly, clone 256.3mo.9C
matched the consensus of the 3-month strain-specific SGA and
was assumed to represent the transmitted/founder superinfecting
(SU) virus. Pseudotyped viruses were assessed for neutralization
sensitivity against longitudinal plasma collected over 21 time
points, at least every 3 months from enrollment to 4 years p.i. The
neutralizing antibody response against each envelope clone, in-
cluding the PI and SU viruses, is shown in Fig. 2A, with the colored
arrows indicating the time point from which clones in the match-
ing color were amplified.
Neutralizing antibodies were first detected at 23 weeks postin-
fection, targeting both the PI and SU viruses with similarly low
titers (ID50 of approximately 1:300). Titers against the PI virus
remained at approximately this level for the next 4 years. In con-
trast, the NAb response against the SU virus became considerably
more potent, reaching extremely high titers of 1:45,000 by 69
weeks of infection. This sudden increase suggested the develop-
ment of a novel neutralizing specificity directed predominantly at
the superinfecting virus.
Titers against viruses cloned from later time points were also
measured using longitudinal plasma. None of the later clones ex-
hibited sensitivity matching that of the SU virus, with peak titers
against the later clones generally being less than 1:4,000. The tim-
ing of the response against the 6-month clones (pink) matched
that of the high-titer response targeting the SU virus, although
titers were substantially lower. Neutralization curves for the 12-
and 21-month viruses were shifted to the right, with little or no con-
temporaneous neutralization, consistent with ongoing neutralization
escape. However, interestingly, many of the 39-month clones showed
no further shift rightwards compared to the 21-month clones and
exhibited increased neutralization by contemporaneous plasma. In-
deed, some 39-month clones were sensitive to neutralization (albeit
at low titers) by plasma from as much as 100 weeks earlier (Fig. 2A).
This finding of contemporaneous neutralization, and even neutral-
ization of later viruses by plasma from much earlier time points, was
suggestive of incomplete viral escape.
CAP256 NAbs target the V1V2 region of both infecting vi-
ruses. Given that we had previously shown that the BCN response
in CAP256 was directed at the V1V2 region (31), we asked
whether the overall autologous NAb response to CAP256 viruses
was also directed at this region. We therefore constructed chime-
ric viruses, whereby the V1V2 regions of the PI and SU viruses
were transferred into a neutralization-resistant heterologous vi-
rus, CAP84 (4). Chimeric viruses were tested against autologous
plasma for neutralization sensitivity and compared to the parental
viruses (Fig. 2B).
The chimera containing the V1V2 region from the PI virus
showed low-level neutralization sensitivity but only from 42
weeks p.i. onwards, with the neutralization profile thereafter
matching that of the parental virus (Fig. 2B, compare gray curves).
As the autologous NAb response against the PI virus was detect-
FIG 1 Schematic indicating the CAP256 viral load (VL; in RNA copies/ml)
from enrollment to 4 years p.i. Dotted lines indicate the time points at which
single-genome amplification (SGA) and sequencing was performed. Open
squares indicate the samples used for strain-specific SGA to determine the
timing of the superinfection. Arrows indicate the time point at which clones
were amplified. ARVs, start of antiretroviral treatment.
Moore et al.
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able earlier, at 23 weeks p.i., this suggested an initial neutralizing
response of unknown specificity, which was followed by a second
low-titer NAb response mediated by anti-V1V2 antibodies. Simi-
larly, the SU V1V2 chimera became sensitive to neutralization at
38 weeks p.i., thereafter showing high-level sensitivity almost ex-
actly matching that of the parental virus (Fig. 2B, compare purple
curves). As with the PI virus, the SU virus was also weakly neutral-
ized initially by an unknown specificity. This was followed by an
extremely high-titer V1V2 response. Therefore, like the BCN re-
sponse in CAP256, the overall autologous neutralizing response
from 38 weeks to 4 years postinfection was mediated largely by
anti-V1V2 antibodies.
The superinfecting virus is highly sensitive to BCN anti-V2
NAbs. The observation that the PI and SU viruses were sensitive to
CAP256 plasma but that the SU virus was 1,000 times more sen-
sitive led us to question the overall neutralization phenotype of
these two distinct primary viruses. Both the PI and SU virus enve-
lope clones were tested against 10 HIV plasma samples obtained
from chronically infected individuals through the South African
National Blood Services (40). Figure 3A shows that while some
plasma samples preferentially neutralized one virus over the other
(e.g., SAC3 neutralized SU virus better than the PI virus, and
SAC61 preferentially neutralized PI over SU virus), overall there
was no significant difference in their neutralization sensitivity
(geometric mean titer of 197 for the SU virus and 156 for the PI
virus), suggesting that both exhibited a tier-2 neutralization phe-
notype (41). These viruses were also tested against monoclonal
antibodies targeting CD4bs (b12 and VRC01), MPER (4E10), a
glycan-dependent epitope in C3 (PGT128), and the V2 loop (PG9,
PG16, and PGT145) (Fig. 3B). The PI virus, but not the SU virus,
was sensitive to b12, although both viruses were neutralized by the
more potent VRC01 and were also equivalently sensitive to 4E10
and PGT128. However, in contrast, the SU virus was nearly 1,000
times more sensitive to PG9 and nearly 10,000 times more sensi-
tive to PG16, both of which target the conserved elements in the
V2 loop. PGT145 showed a similar, though less striking, trend,
with the SU virus being 27 times more sensitive than the PI virus.
Therefore, the much higher anti-V2 titers in CAP256 plasma
FIG 2 (A) Neutralization escape in CAP256. Neutralization sensitivity of multiple autologous CAP256 Env-pseudotyped viruses derived from envelope clones
at 1, 3, 6, 12, 21, and 39 months postinfection. Each clone was tested against longitudinal autologous plasma. Colored arrows indicate the time point at which
clones were amplified. Neutralization titers (ID50) are plotted on a logarithmic scale. (B) The autologous neutralizing response is largely directed against V1V2.
Chimeric constructs containing only V1V2 on both the initial infecting and superinfecting viruses, placed in a neutralization-resistant backbone, were used to
generate Env-pseudotyped viruses, which were tested against longitudinal CAP256 plasma. The onset of the V1V2 response and of the BCN antibodies (31) are
shown with dotted lines.
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against the SU virus were determined by the presence and/or ac-
cessibility of the PG9/16 epitope on the SU virus compared to the
PI virus, rather than more universal determinants of sensitivity,
such as those exhibited by tier-1 viruses (41).
Recombination in V1V2 and gp41 drives rapid evolution of
CAP256 sequences. We examined the evolution of CAP256 viral
sequences over time in the context of the known BCN antibody
response targeting the V2 region. Figure 4A shows an amino acid
highlighter plot illustrating the relationship between the PI virus
(shown with gray shading), the superinfecting strain, and later
viruses. By 6 months, the sampled viral population was comprised
entirely of recombinant viruses, with most of the envelope (except
the V1V2 region and part of the carboxyl terminus of the gp41)
derived from the superinfecting virus. By 12 months, multiple
different recombinant populations existed. Approximately two-
thirds of the 12-month viruses contained V1 and part or all of V2
from the PI virus. The remaining 12-month sequences contained
the V1V2 region from the superinfecting virus, with the gradual
accumulation of amino acid mutations within the V1V2 regions.
In addition, many 12-month viruses also contained the C5 region
of gp120, the gp120-gp41 cleavage site, the gp41 fusion peptide,
and other isolated parts of gp41 from the immunodominant re-
gion, through the carboxy-terminal heptad repeat region and
membrane proximal external region but excluding the amino-
terminal heptad repeat region. By 21 and 39 months postinfec-
tion, all but 1 sequence contained the bulk of gp41 from the PI
virus, suggesting a benefit to the recombinant virus in maintaining
this segment. However, interestingly, both viruses with the entire
V1V2 region derived from the PI or SU virus persisted throughout
the course of infection. All viral clones were predicted by three
coreceptor prediction tools to use the CCR5 coreceptor through-
out the course of infection.
Evolution within the FN/LRD-K-K motif in V2, the target of
CAP256 BCN antibodies. We have previously shown that the
CAP256 BCN specificity depends on residues in the V2 region,
namely, F159, N160, L165, R166, D167, K169, and K171 (forming
the FN/LRD-K-K motif) (31). As the overall autologous response,
like the BCN specificity, was largely directed at V2, we assessed
whether residues that formed the BCN epitope were mutated in
later autologous viruses. Figure 4B shows a detailed amino acid
highlighter analysis of the CAP256 V1V2 sequences, highlighting
the location of the FN/LRD-K-K motif. This motif was present in
the SU but was incomplete in the PI virus. By 6 months, all se-
quences had changes within the FN/LRD-K-K motif, which were
introduced by recombination with the PI virus. However, from 12
months onwards, mutations in V2 and specifically in the FN/
LRD-K-K motif occurred through recombination with the PI vi-
rus and/or through point mutations (absent from both the pri-
mary and superinfecting viruses).
By 39 months postinfection, the CAP256 viral population had
formed two distinct clusters (Fig. 5). These two lineages could be
clearly differentiated from one another both on the basis of neu-
tralization sensitivity and by sequence changes within the FN/
LRD-K-K motif. Cluster 1 clones (39mo.C2, 39mo.F10, 39mo.E1,
and 39mo.H1) (Fig. 6A) were sensitive to neutralization at low
titers by plasma from 2 years earlier. In contrast, cluster 2 clones
(39mo.F1, 39mo.F11, 39mo.F10, and 39mo.F4) (Fig. 6B) exhib-
ited a neutralization profile more consistent with complete neu-
tralization escape, although two of these clones (39mo.F1 and
39mo.F11) also exhibited relatively high titers (ID50 of 282 and
973, respectively) when tested against contemporaneous plasma.
Of note, clones 39mo.4 and 39mo.10 of cluster 2 were completely
resistant to neutralization by contemporaneous plasma, empha-
sizing the fact that complete escape from the CAP256 BCN NAbs
was possible. They did, however, show susceptibility to later
plasma antibodies.
Viruses from cluster 1, epitomized by 39mo.C2, contained 6
mutations in the FN/LRD-K-K motif compared to the superin-
FIG 3 Comparison of the overall neutralization sensitivity of the primary infecting virus and the superinfecting virus against polyclonal subtype C plasma (A)
and broadly neutralizing monoclonal antibodies (B). The geometric mean titer (GMT) of each virus is indicated in parentheses.
Moore et al.
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fecting virus (Fig. 6A). Four of these mutations (A161T, T162I,
L165V, and K169Q) were present in the PI virus with identical
codon usage, suggesting they were introduced through viral re-
combination. The observation that the PI virus was relatively re-
sistant to neutralization (Fig. 2A) suggested that recombination
provided a mechanism for neutralization escape. However, in ad-
dition to these 4 changes, cluster 1 sequences also contained an
R166S and K171N mutation within this region that were not pres-
ent in the PI virus and therefore presumably arose by substitution
after recombination had occurred. In contrast, the viruses in clus-
ter 2 had V2 regions that generally matched the superinfecting
virus, with only two substitutions in the FN/LRD-K-K motif,
namely, L165V (also present in the PI virus) (or T163S) in con-
junction with K169E that arose by substitution.
Changes within the FN/LRD-K-K motif mediate viral escape
from autologous NAb responses. We selected one clone from
each lineage at 39 months, 256.39mo.C2 (cluster 1) and
256.39mo.F1 (cluster 2), to establish whether the changes ob-
served in the region containing the FN/LRD-K-K region mediated
neutralization escape. Mutations observed in the region spanning
positions 159 to 171 (encompassing the FN/LRD-K-K motif) in
either clone were introduced singly or in combination into the
highly sensitive SU virus. These were used to generate pseudovi-
ruses and tested for sensitivity to longitudinal autologous plasma
to determine if they rendered the SU virus less sensitive to neu-
tralization.
In the cluster 1 clone, the T162I change (which removes the
glycan at position 160 that is important for binding to PG9/PG16-
like antibodies) and the K171N mutations, introduced singly, had
moderate effects on neutralization sensitivity, with titers reduced
4-fold from 1:31,000 to approximately 1:7,000 at 39 months p.i.
(Fig. 7A). However, of note, the kinetics of the neutralization
curves of these 2 mutants differed. The K171 mutation had a mod-
erate effect on titers at all time points, while the effect of the T162I
mutation was more pronounced before the onset of breadth (with
titers reduced 18-fold from 11,760 to 645). Thereafter and corre-
sponding with the onset of breadth, the effect of this mutation was
reduced, with neutralization titers increasing 10-fold to 1:7,000,
suggesting that the initial anti-V2 NAb depended more heavily on
the glycan at position 160, while the later BCN antibodies had
reduced dependence on the N160 glycan.
The K169Q mutation had a slightly greater effect on neutral-
FIG 4 Amino acid highlighter plot comparing the initial infecting virus, the superinfecting virus, and viruses isolated from subsequent time points for the entire
envelope gene (A) and specifically the V2 region, including the FN/LRD-K-K motif (B). Gray shading indicates regions matching the initial infecting virus and
highlights recombination, which occurs predominantly in V1V2 and in gp41.
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ization titers than either T162I or K171N, with a 7-fold decrease in
titers at 39 months p.i. This effect waned slightly over 4 years of
infection. In contrast, as previously reported for the BCN speci-
ficity (31), an R166S mutation consistently and profoundly re-
duced the neutralization titers 50-fold from 31,614 to 654 at the
39-month time point. The A161T mutation within the SU virus
resulted in a virus unable to efficiently infect cells, therefore it
could not be evaluated. We also tested constructs containing cer-
tain combinations of multiple mutations within the FN/LRD-K-K
region. However, the introduction of K169Q and K171N along
with the R166S mutation had no further effect on neutralization
titers. Addition of the T162I mutation to the triple mutant re-
sulted in a noninfectious virus that could not be tested. Overall,
these data suggested that the most important escape mutation in
cluster 1 viruses was the R166S mutation (Fig. 7A). Nonetheless,
the residual neutralization of mutants suggests the presence of
unidentified escape mutations elsewhere.
We similarly analyzed changes in the FN/LRD-K-K region in
cluster 2 where only 2 mutations were observed, namely, L165V
and K169E. As described above, these mutations were introduced
FIG 5 Phylogenetic tree of CAP256 showing the development by 39 months postinfection of distinct lineages, cluster 1 and cluster 2. Gray shading indicates
sequences cloned for phenotypic assays. Inset are sequences of part of V2, including the FN/LRD-K-K motif for the SU virus, and a representative of cluster 1
(256.39mo.C2; indicated by an asterisk) and of cluster 2 (256.39mo.F1; double asterisks), highlighting potential escape mutations.
FIG 6 Comparison of the neutralization curves of 39-month viruses from cluster 1 (A) and cluster 2 (B). Partial V2 sequences for cloned viruses are shown below
and are aligned to the superinfecting virus.
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singly and jointly into the sensitive SU virus. The L165V mutation
had only a slight effect (2-fold) on neutralization titers (Fig. 7B).
This substitution therefore did not appear to contribute signifi-
cantly to viral escape in CAP256. In contrast, the effect of the
K169E mutation was substantial, reducing titers to less than
1:1,000 at all time points. Combining the K169E mutation with
the L165V mutation had no additional affect, suggesting that in
cluster 2, viral escape from this specificity was driven largely by a
single change at K169E, though as with cluster 1 viruses, residual
neutralization sensitivity implicated residues yet to be identified
elsewhere. Overall, CAP256 appeared to escape from the domi-
nant V2-dependent NAb specificity through two distinct path-
ways, with mutations either at residue 166 (cluster 1) or 169 (clus-
ter 2) within the V2 region.
The moderate resistance imparted by the K169Q change,
which was present in many of the earlier sequences (see Fig. S1 in
the supplemental material), suggested that recombination with
the V2 region from the PI virus (containing the K169Q mutation)
provided the SU virus with an initial pathway to viral escape, re-
ducing sensitivity 10-fold. However, later clones escaped further
through either an R166S or K169E mutation, further reducing
sensitivity by 10-fold.
Mutations in the C4 region contribute to viral escape in some
CAP256 viruses. To assess whether the unidentified remaining
escape mutations lay within V1V2 or elsewhere, we constructed
chimeras where the V1V2 region from the two 39-month viruses
were transferred into a heterologous neutralization-resistant
backbone, CAP84. Both chimeras, 39mo.C2.V1V2 (cluster 1) and
39mo.F1.V1V2 (cluster 2), were tested for neutralization sensitiv-
ity to longitudinal plasma and showed profound differences in
neutralization sensitivity. The cluster 1 chimera was completely
resistant to neutralization, even at later time points when the pa-
rental 39mo.C2 clone exhibited low-level sensitivity (Fig. 8A).
This observation suggested (i) that the mutations aside from those
identified in the FN/LRD-K-K motif but within the V1V2 region
contributed to escape in this clone, and (ii) that the NAbs respon-
sible for the low-level neutralization of cluster 1 viruses from 75
weeks onwards targeted a region other than V2.
In contrast, the cluster 2 chimera, despite the presence of
K169E, exhibited substantial neutralization sensitivity, with titers
exceeding 1:10,000, similar to that of the SU virus (Fig. 8B). This
result was unexpected and suggested that additional residues out-
side V1V2 were required for escape. Inspection of the entire enve-
lope sequence identified a change to alanine at position 437 in the
C4 region of the envelope that was present only in cluster 2 se-
quences at 39 months. To define the location of residue 437 rela-
tive to V1V2, we fitted a crystal structure of clade C gp120 (PDB-
3LQA) (42) into the cryo-electron microscopy (cryo-EM)
structure of the envelope trimer in an unliganded state (EMD-
5418) (43) using steepest ascent local optimization in UCSF Chi-
mera 1.5.3 (44). The close proximity of residue 437 to the V1V2
region (Fig. 8C and D) supported the possibility that this residue
FIG 7 Mapping mutations that mediate neutralization escape in two representative 39-month clones, 256.39mo.C2 (cluster 1) (A) and 256.39mo.F1 (cluster 2)
(B). Potential escape mutations were introduced by site-directed mutagenesis into the highly sensitive superinfecting virus and tested for neutralization
sensitivity against longitudinal plasma samples from CAP256. Neutralization titers (ID50) are plotted on a logarithmic scale.
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affects neutralization escape. We therefore introduced a P437A
substitution into the chimeric virus to create 39mo.F1.V1V2
P437A. This resulted in a significant drop in neutralization sensi-
tivity, suggesting a role for the C4 region in mediating neutraliza-
tion escape.
DISCUSSION
CAP256 was infected with an HIV-1 subtype C virus and devel-
oped extremely high-titer BCN antibodies recognizing a trimer-
specific epitope in V2 of the envelope glycoprotein (15). In a pre-
vious study, we noted a low-titer autologous response to the
primary infecting virus (1). However, here we used strain-specific
primers to identify the envelope sequence of a second virus that
superinfected CAP256 around 13 to 15 weeks after primary infec-
tion. We showed that like the BCN response, the overall NAb
response to the superinfecting virus was directed almost exclu-
sively at the V2 region, reaching titers similar to those observed
against heterologous viruses. Viral evolution included extensive
recombination between the primary and superinfecting viruses
and resulted in neutralization escape through mutations in V2.
However, low levels of contemporaneous neutralization were
seen, indicating that viral escape from these BCN antibodies was
incomplete. These data suggest that the BCN antibodies in
CAP256 evolved from an earlier strain-specific NAb targeting V2.
We previously showed that antibodies with cross-neutralizing
activity first appeared in the plasma of CAP256 at 53 weeks (31),
only 11 weeks after strain-specific anti-V2 NAbs were detected.
This rapid emergence of BCN antibodies following a strain-spe-
cific response targeting the same region suggested that these early
V2-specific antibodies matured to acquire breadth. This was sup-
ported by our earlier observation that anti-V2 antibodies under-
went subtle changes in specificity over time (31). In this study, the
strain-specific autologous response was considerably more de-
pendent on the glycan at position 160 than later BCN antibodies.
We have previously shown differences in N160 neutralization-
dependent heterologous neutralization by CAP256 plasma (e.g.,
neutralization of CAP45 was N160 dependent, whereas neutral-
ization of ZM53 was not). Interestingly, the glycan at position 160
was not present on the primary infecting virus but was present on
the superinfecting virus (21). Furthermore, at any given time
point thereafter (even with relatively limited sampling using
SGA), the circulating population included variants both with and
without the predicted N-linked glycan at position 160. Thus, the
continuous circulation of viruses heterogeneous for the position
160 glycan may have contributed to the development of BCN
antibodies with variable dependence on this glycan. These data
highlight the possibility that in CAP256, breadth was mediated by
multiple antibodies, all of which were dependent on the residues
at positions 166 and 169 but which differed in their glycan depen-
dence (31). This, in conjunction with the fact that overall anti-V2
titers in CAP256 remained unchanged (which is inconsistent with
the development of an entirely new high-titer specificity), sup-
ports the hypothesis that these BCN antibodies evolved from ex-
isting strain-specific NAbs rather than arising de novo. This would
be encouraging from a vaccination perspective, as it suggests that
FIG 8 Use of chimeric viruses to determine whether neutralization escape is mediated solely by mutations in V1V2 for cluster 1 (A) and cluster 2 viruses (B).
Neutralization titers (ID50) are plotted on a logarithmic scale. The dotted line indicates the time point at which 39-month viruses were amplified (contempo-
raneous time point). Side (C) and top (D) views of the location of the V1V2 region and residue 437 (highlighted in red) within the envelope trimer, determined
by fitting the crystal structure of clade C gp120 (in blue; PDB-3LQA) into the cryo-EM structure of the envelope trimer in an unliganded state (EMD-5418)
(42–44).
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the immune system has the capacity to develop BCN V2-depen-
dent antibodies in a relatively short time. Similar findings were
recently reported from a simian-human immunodeficiency virus-
infected macaque, where BCN antibodies developed within 9
months simultaneously with autologous NAb responses, both of
which were mediated by N332 glycan-dependent antibodies (45).
Both N160- and N332-dependent NAbs are commonly found
among individuals who naturally develop BCN antibodies (11, 13,
23, 24). This finding therefore supports the suggestion by Walker
et al. (45) that glycan-dependent antibodies are more rapidly elic-
ited in natural infection and therefore may be more amenable to
vaccine elicitation.
Two recent studies have shown that superinfection resulted in
greater neutralizing breadth and potency (46, 47). In one of these
studies, broad and potent NAb responses developed in 2 elite neu-
tralizers very soon after infection with a second virus, suggesting
that the development of breadth was accelerated through super-
infection (46). Whether a similar situation provoked the excep-
tional breadth in CAP256 is unknown. It is possible that superin-
fection with a discordant virus results in the broadening of the
NAb response to multiple epitopes presented on discordant vi-
ruses (48), a model supported by the fact that greatest breadth was
associated with intersubtype superinfection (46, 47). It is also pos-
sible that superinfection focuses the NAb response onto conserved
epitopes common to both infecting viruses. The latter scenario
seems unlikely in the case of CAP256, however, as the secondary,
high-titer NAb response which developed in response to the su-
perinfecting virus did not result in any detectable increase in NAb
titers toward the initial infecting virus. However, superinfection in
CAP256 was associated with a massive increase in neutralizing
titers directed to the superinfecting virus, similar to the response
in a superinfected elite neutralizer, QA013, reported previously
(49). This is in contrast to a recent study which showed no en-
hancement of autologous NAb responses in superinfected indi-
viduals (48). Overall, it is not clear if or how superinfection con-
tributed to the exceptional breadth in CAP256.
What is clear is that superinfection in CAP256 resulted in ex-
tensive recombination and significant diversity in the envelope
gene and probably facilitated neutralization escape. Interestingly,
recombination was predominantly in two regions, with the highly
sensitive superinfecting virus acquiring the V1V2 region and gp41
from the less sensitive primary virus. Given that the neutralizing
response in CAP256 was almost entirely directed at V2, this sug-
gested that recombination contributed to neutralization escape.
Detailed characterization of the CAP256 viral populations identi-
fied two distinct viral lineages by 39 months of infection, with
neutralization escape pathways differing between the two lineages.
Cluster 1 viruses contained the V1V2 region of the primary virus
in the superinfecting background, including a glutamine at resi-
due 169, which was known to be crucial for the BCN epitope.
However, although the presence of this glutamine reduced neu-
tralization sensitivity somewhat, this mutation alone was not suf-
ficient to mediate complete neutralization escape. A later R166S
substitution substantially further reduced sensitivity. Thus, al-
though recombination may have provided an initial, rapid path-
way to reduce titers, this was not sufficient in the face of high-titer
NAb responses to this region. In contrast, cluster 2 viruses escaped
from the neutralizing response largely through a K169E substitu-
tion. Previous mapping data had shown that within the FN/LRD-
K-K motif targeted by CAP256 BCN antibodies, the two positions
most crucial for the formation of the epitope were R166 and K169.
Mutations at either of these sites had a profound effect on BCN
activity. In the ConC backbone, an R166A mutation resulted in a
100-fold reduction in neutralization, from a titer of 1:14,057 to
1:137. Similarly, a K169E mutation resulted in a 79-fold titer re-
duction to 1:179 (31). The observation that viral escape from au-
tologous responses (by either of the two evolutionary pathways
observed) occurred through mutations at positions 166 and 169
that form the basis of the BCN epitope (31) suggests that these
responses targeted overlapping epitopes and further supports the
notion that the strain-specific autologous response have evolved
to acquire the capacity to neutralize heterologous viruses.
In addition to mutations at sites 166 and 169 in the V2 region,
we also showed that a mutation at the highly conserved 437 resi-
due in the C4 region contributed to viral escape. The presence of
an alanine at position 437 is rare. Of 989 subtype C sequences from
the Los Alamos sequence database, 967 (97.8%) have a P at posi-
tion 437. The remaining sequences contain S (n  12; 1.2%) or N
(n  8; 0.8%), with alanine present in only 2 sequences (0.2% of
sequences). Furthermore, a linkage between E169 and mutations
at position 437 is supported by the observation that of sequences
with 169E, 13% (7/54) have a residue other than P, compared to
only 1.2% (8/653) in viruses with 169K, suggesting that there is
some enrichment of residues other than P at position 437 in vi-
ruses that have 169E (P  0.001 by Fischer’s exact test). This
finding is consistent with a number of previous studies that
showed a functional interaction between the C4 and V2 regions,
resulting in the modulation of neutralizing epitopes in V2 (50–
54). The enrichment of mutations at this site in sequences that
contain the K169E mutation further suggests an interaction be-
tween these two sites. This is further supported by the close prox-
imity of residue 437 in the C4 region to the V2 region within the
trimeric form of the envelope. It is still not clear, however, whether
C4 forms part of the antibody epitope or plays a more indirect role
in modulating the structure of the V2 region, as has been sug-
gested for less broad anti-V2 NAbs that target an epitope overlap-
ping that of CAP256 (51).
Our observation that many of the 39-month viruses remained
sensitive to plasma antibodies that arose 2 years earlier, a time
point that corresponded to the development of BCN antibodies,
indicated the possibility of incomplete viral escape, especially
among cluster 1 viruses. The neutralization resistance of the chi-
meric virus 39mo.C2.V1V2 (a resistant heterologous virus with
the 256.39mo.C2 virus V1V2) suggests that this residual neutral-
ization sensitivity can be attributed to an undefined second spec-
ificity outside V1V2. Nonetheless, the finding that six of eight
39-month viruses remained sensitive to neutralization by contem-
poraneous plasma at titers as high as 1:1,280 highlights the possi-
bility that such titers do not play a significant role in vivo. This is
supported by the finding in other cohorts that superinfection oc-
curred despite preexisting titers against the superinfecting strain
that exceeded 1:1,300 (49). Furthermore, estimates of protective
titers of antibodies derived from a passive immunization study
using neutralizing monoclonal antibodies suggested that in the
context of chronic infection (unlike acute infection), titers ex-
ceeding 1:1,000 were required to control viremia (55). Perhaps
more significantly, the complete absence of contemporaneous
neutralization against two of eight 39-month clones highlights
that neutralization escape from the CAP256 NAbs was certainly
possible. The fact that fully escaped variants were not preferen-
HIV Escape from Broadly Neutralizing Antibodies
May 2013 Volume 87 Number 9 jvi.asm.org 4891
 on N
ovem







tially selected suggests either that complete escape incurred some
fitness cost or that incomplete escape did not incur a similar cost.
If this is the case, this may have implications for the use of mono-
clonal antibodies in passive immunization protocols, particularly
in the context of chronic infection.
Interest in the ontogeny of V2 antibodies has intensified since
the demonstration that they correlated with protection from HIV
infection in the RV144 trial (29). Sieve analysis of break-through
infections in RV144 identified immune pressure at position 169
(30), and monoclonal antibodies isolated from RV144 vaccinees
were dependent on this residue. Whether the antibodies we de-
scribe in CAP256 are related to those in RV144 remains to be
determined. The frequency of K169-dependent binding and neu-
tralizing antibodies in natural infection is not known, but our data
show that dependence on this residue is not limited to BCN anti-
bodies. Nevertheless, understanding the ontogeny of V2 antibod-
ies and their escape mechanisms could be valuable in improving
vaccine design.
Overall, these studies highlight the dynamic relationship be-
tween autologous and heterologous specificities and underline the
possibility of viral escape even from BCN antibodies targeting
conserved epitopes. The role of superinfection, if any, in driving
rapid development of BCN responses warrants further study. The
consistent targeting of the same epitope by strain-specific and,
later, BCN antibodies suggests rapid maturation of these re-
sponses to acquire breadth, with implications for vaccine elicita-
tion of such specificities. Thus, isolation and characterization of
CAP256 BCN monoclonal antibodies and their precursors will be
most informative.
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